about
Neurologic manifestations of chronic methamphetamine abuseLow concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic studyParkinsonism in patients with a history of amphetamine exposure.The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.Gastrodia elata bl attenuates methamphetamine-induced dopaminergic toxicity via inhibiting oxidative burdens.Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERKMethamphetamine regulation of sulfotransferase 1A1 and 2A1 expression in rat brain sectionsNeurologic manifestations of chronic methamphetamine abuse.Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.Review: The neuropathology of drug abuse.The Basal Ganglia as a Substrate for the Multiple Actions of AmphetaminesParkinson's disease: is it a toxic syndrome?Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity.Methamphetamine and Parkinson's disease.Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge.Development of Parkinson's disease in patients with Narcolepsy.The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.
P2860
Q24624506-E893401B-D35D-41D0-B6C5-85128AFA6687Q28477457-DDEB18C2-F713-45B8-BD3C-318C927F2927Q33698983-29FDE8F7-E4C5-4103-A40F-9EA39D8C99E2Q34025177-130578DE-49E3-4F44-95AC-2E89B6AA98F4Q35107739-25EEF759-B420-4AA6-8B36-D895A29243CFQ36476821-CDA0B466-6150-4D4F-A4E6-BC0EE33965B5Q36569909-86F5712D-DFE8-4E4C-84FD-2CA89681D21AQ37150547-C53FCC1D-6ED4-41A1-8CB8-8BD1451AACC4Q37423949-C6F89CE0-E4CB-40AC-BDEB-A4B54AE9A5CAQ37800120-29774F4F-3522-470E-AB8B-B4DDEDFCF8DEQ37909050-87D3B251-9E29-48F9-904B-49B49BB47AB4Q39806409-25881783-54F5-4D19-ADD4-1067D9B74EDAQ40110666-4C277FBB-DD73-41E5-AF5D-E0B89E7E550EQ41860851-CE59AE31-5D1C-473A-BDB8-B76613EAD1CEQ42707394-811B6469-AF2B-411B-90F4-2FA6014930AAQ43848498-DBB06BD1-AF24-446D-9FEB-C6F35283B0C4Q46021189-67435776-16E0-4E28-AF43-E0BED86323A6Q47845016-3F3C40CF-622E-4DC5-92DF-56A706C5473D
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Is methamphetamine abuse a risk factor in parkinsonism?
@ast
Is methamphetamine abuse a risk factor in parkinsonism?
@en
Is methamphetamine abuse a risk factor in parkinsonism?
@nl
type
label
Is methamphetamine abuse a risk factor in parkinsonism?
@ast
Is methamphetamine abuse a risk factor in parkinsonism?
@en
Is methamphetamine abuse a risk factor in parkinsonism?
@nl
prefLabel
Is methamphetamine abuse a risk factor in parkinsonism?
@ast
Is methamphetamine abuse a risk factor in parkinsonism?
@en
Is methamphetamine abuse a risk factor in parkinsonism?
@nl
P921
P1433
P1476
Is methamphetamine abuse a risk factor in parkinsonism?
@en
P2093
Guilarte TR
P304
P356
10.1016/S0161-813X(01)00046-8
P577
2001-12-01T00:00:00Z